Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Kimbell Royalty Partners Q3 net income falls 23% year over year to $17.25 million

Kimbell Royalty Partners Q3 net income falls 23% year over year to $17.25 million

BitgetBitget2026/11/05 12:13
  • Kimbell Royalty Partners’ third-quarter 2026 net income fell 23% year-over-year to $17.25 million, while total revenues rose 7% to $86.33 million.
  • Daily production reached a record 27,565 barrels of oil equivalent, including 41 days of production from the Drop Down acquisition.
  • The partnership plans to redeem 50% of remaining Series A Cumulative Convertible Preferred Units for approximately $100.2 million.
  • Management expects materially higher fourth-quarter 2026 cash flow based on current-quarter oil prices; approximately 84% of estimated oil production is unhedged.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kimbell Royalty Partners LP published the original content used to generate this news brief via PR Newswire (Ref. ID: DA89591) on November 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss